Document is current
Any future updates will be listed below
-
Authors
Aznar, Maria Angela https://orcid.org/0000-0002-7970-1672
Molina, Carmen
Teijeira, Alvaro
Rodriguez, Inmaculada
Azpilikueta, Arantza
Garasa, Saray
Sanchez‐Paulete, Alfonso R
Cordeiro, Luna
Etxeberria, Iñaki
Alvarez, Maite
Rius‐Rocabert, Sergio
Nistal‐Villan, Estanislao
Berraondo, Pedro
Melero, Ignacio https://orcid.org/0000-0002-1360-348X
-
Funding
Funding for this research was provided by:
Spanish Ministry of Economy and Competitiveness MEC (SAF2014‐52361‐R)
Spanish Ministry of Economy and Competitiveness MEC (SAF2017–83267‐C2–1‐R)
Fundación Científica Asociación Española Contra el Cáncer
Cancer Research Institute
Fundación BBVA
- License Information
-
More Information
Article History
Received: 25 January 2019
Revised: 22 October 2019
Accepted: 24 October 2019
First Online: 19 November 2019
Conflict of interest
: IM reports receiving commercial research grants from BMS, Alligator, and ROCHE and serves as a consultant/advisory board member for BMS, Merck‐Serono, Roche‐Genentech, Genmab, Incyte, Bioncotech, Tusk, Molecular partners F‐STAR, Alligator, Bayer, Numab, Immunedesign, and AstraZeneca.
